Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.

MLA

Yonemori, Kan, et al. “Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus Pembrolizumab versus Treatment of Physician’s Choice Chemotherapy in Patients with Previously Treated Advanced or Recurrent Endometrial Cancer.” Journal of Gynecologic Oncology, vol. 35, no. 2, Mar. 2024, p. e40. EBSCOhost, https://doi.org/10.3802/jgo.2024.35.e40.

APA

Yonemori, K., Fujiwara, K., Hasegawa, K., Yunokawa, M., Ushijima, K., Suzuki, S., Shikama, A., Minobe, S., Usami, T., Kim, J.-W., Kim, B.-G., Wang, P.-H., Chang, T.-C., Yamamoto, K., Han, S., McKenzie, J., Orlowski, R. J., Miura, T., Makker, V., & Man Kim, Y. (2024). Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Journal of Gynecologic Oncology, 35(2), e40. https://doi.org/10.3802/jgo.2024.35.e40

Chicago

Yonemori, Kan, Keiichi Fujiwara, Kosei Hasegawa, Mayu Yunokawa, Kimio Ushijima, Shiro Suzuki, Ayumi Shikama, et al. 2024. “Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus Pembrolizumab versus Treatment of Physician’s Choice Chemotherapy in Patients with Previously Treated Advanced or Recurrent Endometrial Cancer.” Journal of Gynecologic Oncology 35 (2): e40. doi:10.3802/jgo.2024.35.e40.